gdc

Leukemia

Acalabrutinib versus Ibrutinib in Previously Treated CLL
CLL Monthly MinutesLeukemia
The first head-to-head trial of these drugs shows comparable efficacy with a better cardiovascular safety profile for acalabrutinib.
Protecting Patients with CLL from COVID-19
CLL Monthly MinutesLeukemia
A recent study provides some of the first data on COVID-19 vaccine efficacy in patients with chronic lymphocytic leukemia.
Promising Data on Zanubrutinib in Previously Treated CLL
CLL Monthly MinutesLeukemia
Preliminary results from the ongoing ALPINE study suggest that zanubrutinib may have superior efficacy and an improved safety profile compared with ibrutinib in previously treated patients with chronic lymphocytic leukemia.
Acalabrutinib Shows Superior Efficacy Over Chemoimmunotherapy
CLL Monthly MinutesLeukemia
Results from the 4-year follow-up of the ELEVATE-TN study support acalabrutinib with or without immunotherapy in previously untreated patients with chronic lymphocytic leukemia.
Maintaining an Intimate Relationship After a Cancer Diagnosis
CLL Monthly MinutesLeukemia
Being diagnosed with cancer and undergoing subsequent treatment can be challenging for patients and their partners, but intimacy does not have to end.
FDA Approved Rylaze as Part of a Treatment Regimen for Young Patients with Leukemia or Lymphoma
FDA Approvals, News & UpdatesLeukemiaLymphoma
In June 2021, the FDA approved Rylaze (asparaginase erwinia chrysanthemi [recombinant]-rywn), an asparagine-specific enzyme, to be used as part of a multi-drug chemotherapy regimen for patients older than 1 month with acute lymphoblastic leukemia or lymphoblastic lymphoma who are hypersensitive to asparaginase caused by E. coli infection.
A Look at Acalabrutinib Clinical Trials
CLL Monthly MinutesLeukemia
Ongoing clinical trials are poised to expand the role of acalabrutinib in treating chronic lymphocytic leukemia.
What Your Doctor Should Know About Your Quality of Life
CLL Monthly MinutesLeukemia
Chronic lymphocytic leukemia can have a negative effect on patients’ quality of life, but healthcare teams may be able to minimize the impact.
Lowering the Dose May Not Mean Less Effective Treatment
CLL Monthly MinutesLeukemia
Low-dose chemoimmunotherapy may be an effective first-line therapy for certain patients with chronic lymphocytic leukemia and particular biological and genetic features.
Page 1 of 12
Results 1 - 10 of 111

Subscribe to CONQUER: the patient voice magazine

Receive timely cancer news & updates, patient stories, and more.

Country
Gender
Race or Ethnicity
Profession or Role
Primary Interest